VTGNConference•businesswire•
Vistagen to Present at the TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit
Sentiment:Negative (30)
Summary
(NASDAQ:VTGN) SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced that President and Chief Executive Officer, Shawn Singh, will participate in a fireside chat at the TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry Conference. The Company will also host one-on-one meetings
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on September 9, 2025 by businesswire